

# VasDeBlock medical ApS Announces Issuance of a Patent in Canada

2024.07.09.

**Copenhagen, Denmark. VasDeBlock medical ApS, a medico tech company focusing on the development of a device and methods for long-acting, reversible contraception for men, announces approval of the company's key patent in Canada.**

The issued patent "Occlusion device for reversible occlusion of a biological tube", Canadian Patent no. 2,986,460 covers the company's invention of methods, systems and devices to prevent pregnancy on a long-term basis.

The Canadian patent granted completes the patent family of related patents granted by EP in great parts of Europe together with Australia, Japan and the US.

"We are proud to have secured our non-hormonal, non-surgical, easily reversible contraceptive allowing men to participate in the family planning" says Mette Mikkelsen, CEO of VasDeBlock. "This latest patent approval is an important step in our development of long-acting, reversible male contraception!".

The VasDeBlock patent portfolio encompasses a device and methods for administering it – without need for surgery – to effectively block spermatozoa from reaching the ejaculate and by similar simple means removing the device when protection is no longer needed.

It's a long sought for alternative to traditional male sterilization (vasectomy) and controversial hormonal contraception and has raised great international interest. It will not prevent STDs.

The comprehensive patent coverage secures exclusivity to develop the products and methods. The company's strategy is to actively seek new patentable innovations from its device and method development programs.

